Latest Surrozen News & Updates

See the latest news and media coverage for Surrozen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Surrozen

Biotechnology company developing Wnt-based ophthalmic therapies

surrozen.com

Headquarters: South San Francisco, United States
Company type: Private company
Number of employees: 10–70
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Surrozen

In short: Surrozen filed an IND application for SZN-8141 to treat diabetic macular edema and reported a cash balance of $106.9 million.

Company announcements

August 6 Surrozen

Surrozen reports Q2 2026 financial results and business update

The company plans IND submission for SZN-8141, DUET trial initiation, and highlighted a Boehringer Ingelheim milestone and PTAB patent win.

May 6 Surrozen

Surrozen reports Q1 2026 financial results

Cash at $106.9M. On track for SZN-8141 IND submission H2 2026. Net loss $127.5M.

March 23 Surrozen

Surrozen reports Q4 and full-year 2025 financial results

Pipeline advances with IND submission for SZN-8141 planned for H2 2026. Receives $5M milestone from Boehringer Ingelheim. Strengthens leadership. Cash at $89.2M; net loss $242M.

7 November 2025 Surrozen

Surrozen reports Q3 2025 financial results

Cash stands at $81.3M. Appoints Andrew Maleki as CFO. Advances ophthalmology pipeline with IND for SZN-8141 planned in 2026.

Media coverage

September 8 Yahoo Finance

Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema

Learn more Surrozen (SRZN) said Tuesday that it submitted an investigational new drug application to the US Food and Drug Administration seeking to evaluate SZN-8141...

August 20 ZoneBourse

Surrozen, Inc. : William Blair & Co. optimistic on the file

07/11 Surrozen, Inc.: Financial results for the third quarter and the nine months ended September 30, 2025 CI 07/11 Andrew Maleki appointed director...

August 5 Markets Insider

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026Expect to initiate SZN-8141 Phase 1b/2a...

July 11 AAII

Why Surrozen, Inc.’s (SRZN) Stock Is Up 7.22%

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Surrozen, Inc. before investing...

Never miss news about Surrozen

Track Surrozen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.